Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $13.6 million.

  • Rhythm Pharmaceuticals' Accounts Payables rose 17892.37% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 17892.37%. This contributed to the annual value of $12.3 million for FY2024, which is 15236.44% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Accounts Payables stood at $13.6 million, which was up 17892.37% from $16.0 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Accounts Payables high stood at $16.0 million for Q2 2025, and its period low was $3.8 million during Q3 2023.
  • For the 5-year period, Rhythm Pharmaceuticals' Accounts Payables averaged around $8.1 million, with its median value being $6.0 million (2022).
  • In the last 5 years, Rhythm Pharmaceuticals' Accounts Payables tumbled by 4580.7% in 2024 and then surged by 25179.4% in 2025.
  • Rhythm Pharmaceuticals' Accounts Payables (Quarter) stood at $5.7 million in 2021, then dropped by 16.38% to $4.8 million in 2022, then grew by 1.83% to $4.9 million in 2023, then skyrocketed by 152.36% to $12.3 million in 2024, then increased by 10.57% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $16.0 million for Q2 2025, and $11.9 million during Q1 2025.